The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status

Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling. To proactively identify resistance mechanisms in ALK-positive neuroblastoma (NB), we herein e...

Descripción completa

Detalles Bibliográficos
Autores principales: Trigg, Ricky M., Lee, Liam C., Prokoph, Nina, Jahangiri, Leila, Reynolds, C. Patrick, Amos Burke, G. A., Probst, Nicola A., Han, Miaojun, Matthews, Jamie D., Lim, Hong Kai, Manners, Eleanor, Martinez, Sonia, Pastor, Joaquin, Blanco-Aparicio, Carmen, Merkel, Olaf, de los Fayos Alonso, Ines Garces, Kodajova, Petra, Tangermann, Simone, Högler, Sandra, Luo, Ji, Kenner, Lukas, Turner, Suzanne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883072/
https://www.ncbi.nlm.nih.gov/pubmed/31780656
http://dx.doi.org/10.1038/s41467-019-13315-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883072/
https://www.ncbi.nlm.nih.gov/pubmed/31780656
http://dx.doi.org/10.1038/s41467-019-13315-x

Ejemplares similares